HomeCompareSGFEF vs MRK

SGFEF vs MRK: Dividend Comparison 2026

SGFEF yields 0.47% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $11.0K in total portfolio value
10 years
SGFEF
SGFEF
● Live price
0.47%
Share price
$100.00
Annual div
$0.47
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.8K
Annual income
$0.05
Full SGFEF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — SGFEF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGFEFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGFEF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGFEF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGFEF
Annual income on $10K today (after 15% tax)
$39.63/yr
After 10yr DRIP, annual income (after tax)
$0.04/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $807.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGFEF + MRK for your $10,000?

SGFEF: 50%MRK: 50%
100% MRK50/50100% SGFEF
Portfolio after 10yr
$25.2K
Annual income
$475.17/yr
Blended yield
1.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SGFEF
Analyst Ratings
2
Buy
2
Hold
Consensus: Buy
Altman Z
5.0
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGFEF buys
0
MRK buys
0
No recent congressional trades found for SGFEF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGFEFMRK
Forward yield0.47%3.25%
Annual dividend / share$0.47$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR-50%8.2%
Portfolio after 10y$19.8K$30.7K
Annual income after 10y$0.05$950.29
Total dividends collected$47.00$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: SGFEF vs MRK ($10,000, DRIP)

YearSGFEF PortfolioSGFEF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,723$23.31$11,192$351.54$469.00MRK
2$11,486$11.68$12,524$392.70$1.0KMRK
3$12,295$5.85$14,015$438.65$1.7KMRK
4$13,159$2.92$15,682$489.96$2.5KMRK
5$14,082$1.46$17,547$547.23$3.5KMRK
6$15,068$0.73$19,632$611.16$4.6KMRK
7$16,123$0.37$21,963$682.53$5.8KMRK
8$17,252$0.18$24,571$762.18$7.3KMRK
9$18,460$0.09$27,486$851.08$9.0KMRK
10$19,752$0.05$30,745$950.29$11.0KMRK

SGFEF vs MRK: Complete Analysis 2026

SGFEFStock

Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production. In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.

Full SGFEF Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this SGFEF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGFEF vs SCHDSGFEF vs JEPISGFEF vs OSGFEF vs KOSGFEF vs MAINSGFEF vs JNJSGFEF vs ABBVSGFEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.